Medically reviewed by Marla Anderson, MD Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

A 51-year-old man with multiple myeloma (diagnosed in December 2019 ... disappearance of any soft-tissue plasmacytomas, less than 5% plasma cells in bone marrow, normal free light-chain ratio ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma cells ...

Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a white blood cell that makes antibodies and helps you fight infection. The cancer occurs when the plasma cells inside ...

Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

"Find joy in all circumstances," the late David Bauer said, quoting Apostle Paul in the Bible. He did that even as he fought multiple myeloma for five years.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ages.